Clinical data | |
---|---|
Trade names | Tapazole, others |
Other names | methimazole (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682464 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 93% |
Protein binding | None |
Metabolism | Liver |
Elimination half-life | 5-6 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.439 |
Chemical and physical data | |
Formula | C4H6N2S |
Molar mass | 114.17 g·mol−1 |
3D model (JSmol) | |
Melting point | 146 °C (295 °F) |
Solubility in water | 275[1] mg/mL (20 °C) |
| |
| |
(verify) |
Thiamazole, also known as methimazole, is a medication used to treat hyperthyroidism.[2] This includes Graves disease, toxic multinodular goiter, and thyrotoxic crisis.[2] It is taken by mouth.[2] Full effects may take a few weeks to occur.[3]
Common side effects include itchiness, hair loss, nausea, muscle pain, swelling, and abdominal pain.[2] Severe side effects may include low blood cell counts, liver failure, and vasculitis.[2] Use is not recommended during the first trimester of pregnancy due to the risk of congenital anomalies, but it may be used in the second trimester or third trimester.[4] It may be used during breastfeeding.[4] Those who developed significant side effects may also have problems with propylthiouracil.[2] Thiamazole is a cyclic thiourea derivative that works by decreasing the production of thyroid hormones.[2]
Thiamazole was approved for medical use in the United States in 1950.[2] It is on the World Health Organization's List of Essential Medicines.[5][6] It is available as a generic medication.[2] It is also available in Europe and Asia.[7] In 2021, it was the 237th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[8][9]